Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.

Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, McGettigan S, Giles LR, Schuchter LM, Seykora JT, Rosenbach M.

J Am Acad Dermatol. 2012 Dec;67(6):1265-72. doi: 10.1016/j.jaad.2012.04.008. Epub 2012 May 18.

2.

Solubilisation of triolein by microemulsions containing C12E4/hexadecane/water: equilibrium and dynamics.

Garrett PR, Carr D, Giles D, Pierre-Louis G, Staples E, Miller CA, Chen BH.

J Colloid Interface Sci. 2008 Sep 15;325(2):508-15. doi: 10.1016/j.jcis.2008.06.014. Epub 2008 Jun 13.

PMID:
18597762
3.

CADRE: the Central Aspergillus Data REpository.

Mabey JE, Anderson MJ, Giles PF, Miller CJ, Attwood TK, Paton NW, Bornberg-Bauer E, Robson GD, Oliver SG, Denning DW.

Nucleic Acids Res. 2004 Jan 1;32(Database issue):D401-5.

4.

A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial).

Giles FJ, Miller CB, Hurd DD, Wingard JR, Fleming TR, Sonis ST, Bradford WZ, Pulliam JG, Anaissie EJ, Beveridge RA, Brunvand MM, Martin PJ; PROMPT-CT Trial Investigators.

Leuk Lymphoma. 2003 Jul;44(7):1165-72.

PMID:
12916869
5.

Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy.

Cella D, Pulliam J, Fuchs H, Miller C, Hurd D, Wingard JR, Sonis ST, Martin PJ, Giles F.

Cancer. 2003 Jul 15;98(2):406-12.

6.

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.

Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien SM, Thomas DA, Andreeff M, Bivins C, Jolivet J, Kantarjian HM.

J Clin Oncol. 2002 Feb 1;20(3):656-64.

PMID:
11821445

Supplemental Content

Loading ...
Support Center